CMS/NCI Collaboration Will Use Cancer As Model For Evidence-Based Reimbursement

Inter-agency task force is examining how to link reimbursement to the “new paradigm” of drug discovery, NCI Director von Eschenbach says. Collaboration builds on an FDA/NCI agreement aimed at speeding development of cancer drugs.